Midday Report: Blueprint Medicines (BPMC) Gains on August 5

Equities Staff  |

Blueprint Medicines Corp (NASDAQ: BPMC) shares are up 13.17%, or $7.86 per share, as on 11:48:53 est today. Since opening the day at $63.87, 226,072 shares of Blueprint Medicines have exchanged hands and the stock has traded between $67.56 and $62.82.  

So far this year the company is down 39.58%.

Blueprint Medicines expects its next earnings on 2022-10-27.

For technical charts, analysis, and more on Blueprint Medicines visit the company profile.

About Blueprint Medicines Corp

Blueprint Medicines is a global precision therapy company that invents life-changing medicines for people with cancer and hematologic disorders. Applying an approach that is both precise and agile, the company creates therapies that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Since 2011, Blueprint has leveraged its research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate science into a broad pipeline of precision therapies. Today, the company is delivering its approved medicines to patients in the United States and Europe, and the company is globally advancing multiple programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy.

To get more information on Blueprint Medicines Corp and to follow the company's latest updates, you can visit the company's profile page here: Blueprint Medicines Corp's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

China, Taiwan and the Boycott
An Easy Way to Profit Off One of Today’s Strongest Sectors
The Future of Smartphones is Still Unfolding: Jeff Kagan
These Stocks are Sending a Signal (Like Amazon in 2008)
It Isn’t a Recession Until This Group of Economists Says So
What You Should Know About Europe's Energy Wars
Meatless Meats and Smokeless Smokes
Mixed Wireless Recovery at AT&T, Verizon, T-Mobile: Jeff Kagan



Market Movers

Sponsored Financial Content